Obesity, but not metabolic syndrome, negatively affects outcome in bipolar disorder

S. L. Mcelroy, D. E. Kemp, E. S. Friedman, N. A. Reilly-Harrington, L. G. Sylvia, J. R. Calabrese, D. J. Rabideau, T. A. Ketter, M. E. Thase, V. Singh, M. Tohen, C. L. Bowden, E. E. Bernstein, B. D. Brody, T. Deckersbach, J. H. Kocsis, G. Kinrys, W. V. Bobo, M. Kamali, M. G. Mcinnis & 4 others A. C. Leon, S. Faraone, A. A. Nierenberg, R. C. Shelton

Research output: Contribution to journalArticle

Abstract

Objective: Examine the effects of obesity and metabolic syndrome on outcome in bipolar disorder. Method: The Comparative Effectiveness of a Second Generation Antipsychotic Mood Stabilizer and a Classic Mood Stabilizer for Bipolar Disorder (Bipolar CHOICE) study randomized 482 participants with bipolar disorder in a 6-month trial comparing lithium- and quetiapine-based treatment. Baseline variables were compared between groups with and without obesity, with and without abdominal obesity, and with and without metabolic syndrome respectively. The effects of baseline obesity, abdominal obesity, and metabolic syndrome on outcomes were examined using mixed effects linear regression models. Results: At baseline, 44.4% of participants had obesity, 48.0% had abdominal obesity, and 27.3% had metabolic syndrome; neither obesity, nor abdominal obesity, nor metabolic syndrome were associated with increased global severity, mood symptoms, or suicidality, or with poorer functioning or life satisfaction. Treatment groups did not differ on prevalence of obesity, abdominal obesity, or metabolic syndrome. By contrast, among the entire cohort, obesity was associated with less global improvement and less improvement in total mood and depressive symptoms, suicidality, functioning, and life satisfaction after 6 months of treatment. Abdominal obesity was associated with similar findings. Metabolic syndrome had no effect on outcome. Conclusion: Obesity and abdominal obesity, but not metabolic syndrome, were associated with less improvement after 6 months of lithium- or quetiapine-based treatment.

Original languageEnglish (US)
Pages (from-to)144-153
Number of pages10
JournalActa Psychiatrica Scandinavica
Volume133
Issue number2
DOIs
StatePublished - Feb 1 2016
Externally publishedYes

Fingerprint

Bipolar Disorder
Obesity
Abdominal Obesity
Lithium
Linear Models
Therapeutics
Antipsychotic Agents
Depression
Abdominal obesity metabolic syndrome

Keywords

  • Bipolar disorder
  • Metabolic syndrome
  • Obesity
  • Outcome

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Mcelroy, S. L., Kemp, D. E., Friedman, E. S., Reilly-Harrington, N. A., Sylvia, L. G., Calabrese, J. R., ... Shelton, R. C. (2016). Obesity, but not metabolic syndrome, negatively affects outcome in bipolar disorder. Acta Psychiatrica Scandinavica, 133(2), 144-153. https://doi.org/10.1111/acps.12460

Obesity, but not metabolic syndrome, negatively affects outcome in bipolar disorder. / Mcelroy, S. L.; Kemp, D. E.; Friedman, E. S.; Reilly-Harrington, N. A.; Sylvia, L. G.; Calabrese, J. R.; Rabideau, D. J.; Ketter, T. A.; Thase, M. E.; Singh, V.; Tohen, M.; Bowden, C. L.; Bernstein, E. E.; Brody, B. D.; Deckersbach, T.; Kocsis, J. H.; Kinrys, G.; Bobo, W. V.; Kamali, M.; Mcinnis, M. G.; Leon, A. C.; Faraone, S.; Nierenberg, A. A.; Shelton, R. C.

In: Acta Psychiatrica Scandinavica, Vol. 133, No. 2, 01.02.2016, p. 144-153.

Research output: Contribution to journalArticle

Mcelroy, SL, Kemp, DE, Friedman, ES, Reilly-Harrington, NA, Sylvia, LG, Calabrese, JR, Rabideau, DJ, Ketter, TA, Thase, ME, Singh, V, Tohen, M, Bowden, CL, Bernstein, EE, Brody, BD, Deckersbach, T, Kocsis, JH, Kinrys, G, Bobo, WV, Kamali, M, Mcinnis, MG, Leon, AC, Faraone, S, Nierenberg, AA & Shelton, RC 2016, 'Obesity, but not metabolic syndrome, negatively affects outcome in bipolar disorder', Acta Psychiatrica Scandinavica, vol. 133, no. 2, pp. 144-153. https://doi.org/10.1111/acps.12460
Mcelroy SL, Kemp DE, Friedman ES, Reilly-Harrington NA, Sylvia LG, Calabrese JR et al. Obesity, but not metabolic syndrome, negatively affects outcome in bipolar disorder. Acta Psychiatrica Scandinavica. 2016 Feb 1;133(2):144-153. https://doi.org/10.1111/acps.12460
Mcelroy, S. L. ; Kemp, D. E. ; Friedman, E. S. ; Reilly-Harrington, N. A. ; Sylvia, L. G. ; Calabrese, J. R. ; Rabideau, D. J. ; Ketter, T. A. ; Thase, M. E. ; Singh, V. ; Tohen, M. ; Bowden, C. L. ; Bernstein, E. E. ; Brody, B. D. ; Deckersbach, T. ; Kocsis, J. H. ; Kinrys, G. ; Bobo, W. V. ; Kamali, M. ; Mcinnis, M. G. ; Leon, A. C. ; Faraone, S. ; Nierenberg, A. A. ; Shelton, R. C. / Obesity, but not metabolic syndrome, negatively affects outcome in bipolar disorder. In: Acta Psychiatrica Scandinavica. 2016 ; Vol. 133, No. 2. pp. 144-153.
@article{5c6c7a81788945d18ab9fc0744e1ce8a,
title = "Obesity, but not metabolic syndrome, negatively affects outcome in bipolar disorder",
abstract = "Objective: Examine the effects of obesity and metabolic syndrome on outcome in bipolar disorder. Method: The Comparative Effectiveness of a Second Generation Antipsychotic Mood Stabilizer and a Classic Mood Stabilizer for Bipolar Disorder (Bipolar CHOICE) study randomized 482 participants with bipolar disorder in a 6-month trial comparing lithium- and quetiapine-based treatment. Baseline variables were compared between groups with and without obesity, with and without abdominal obesity, and with and without metabolic syndrome respectively. The effects of baseline obesity, abdominal obesity, and metabolic syndrome on outcomes were examined using mixed effects linear regression models. Results: At baseline, 44.4{\%} of participants had obesity, 48.0{\%} had abdominal obesity, and 27.3{\%} had metabolic syndrome; neither obesity, nor abdominal obesity, nor metabolic syndrome were associated with increased global severity, mood symptoms, or suicidality, or with poorer functioning or life satisfaction. Treatment groups did not differ on prevalence of obesity, abdominal obesity, or metabolic syndrome. By contrast, among the entire cohort, obesity was associated with less global improvement and less improvement in total mood and depressive symptoms, suicidality, functioning, and life satisfaction after 6 months of treatment. Abdominal obesity was associated with similar findings. Metabolic syndrome had no effect on outcome. Conclusion: Obesity and abdominal obesity, but not metabolic syndrome, were associated with less improvement after 6 months of lithium- or quetiapine-based treatment.",
keywords = "Bipolar disorder, Metabolic syndrome, Obesity, Outcome",
author = "Mcelroy, {S. L.} and Kemp, {D. E.} and Friedman, {E. S.} and Reilly-Harrington, {N. A.} and Sylvia, {L. G.} and Calabrese, {J. R.} and Rabideau, {D. J.} and Ketter, {T. A.} and Thase, {M. E.} and V. Singh and M. Tohen and Bowden, {C. L.} and Bernstein, {E. E.} and Brody, {B. D.} and T. Deckersbach and Kocsis, {J. H.} and G. Kinrys and Bobo, {W. V.} and M. Kamali and Mcinnis, {M. G.} and Leon, {A. C.} and S. Faraone and Nierenberg, {A. A.} and Shelton, {R. C.}",
year = "2016",
month = "2",
day = "1",
doi = "10.1111/acps.12460",
language = "English (US)",
volume = "133",
pages = "144--153",
journal = "Acta Psychiatrica Scandinavica",
issn = "0001-690X",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Obesity, but not metabolic syndrome, negatively affects outcome in bipolar disorder

AU - Mcelroy, S. L.

AU - Kemp, D. E.

AU - Friedman, E. S.

AU - Reilly-Harrington, N. A.

AU - Sylvia, L. G.

AU - Calabrese, J. R.

AU - Rabideau, D. J.

AU - Ketter, T. A.

AU - Thase, M. E.

AU - Singh, V.

AU - Tohen, M.

AU - Bowden, C. L.

AU - Bernstein, E. E.

AU - Brody, B. D.

AU - Deckersbach, T.

AU - Kocsis, J. H.

AU - Kinrys, G.

AU - Bobo, W. V.

AU - Kamali, M.

AU - Mcinnis, M. G.

AU - Leon, A. C.

AU - Faraone, S.

AU - Nierenberg, A. A.

AU - Shelton, R. C.

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Objective: Examine the effects of obesity and metabolic syndrome on outcome in bipolar disorder. Method: The Comparative Effectiveness of a Second Generation Antipsychotic Mood Stabilizer and a Classic Mood Stabilizer for Bipolar Disorder (Bipolar CHOICE) study randomized 482 participants with bipolar disorder in a 6-month trial comparing lithium- and quetiapine-based treatment. Baseline variables were compared between groups with and without obesity, with and without abdominal obesity, and with and without metabolic syndrome respectively. The effects of baseline obesity, abdominal obesity, and metabolic syndrome on outcomes were examined using mixed effects linear regression models. Results: At baseline, 44.4% of participants had obesity, 48.0% had abdominal obesity, and 27.3% had metabolic syndrome; neither obesity, nor abdominal obesity, nor metabolic syndrome were associated with increased global severity, mood symptoms, or suicidality, or with poorer functioning or life satisfaction. Treatment groups did not differ on prevalence of obesity, abdominal obesity, or metabolic syndrome. By contrast, among the entire cohort, obesity was associated with less global improvement and less improvement in total mood and depressive symptoms, suicidality, functioning, and life satisfaction after 6 months of treatment. Abdominal obesity was associated with similar findings. Metabolic syndrome had no effect on outcome. Conclusion: Obesity and abdominal obesity, but not metabolic syndrome, were associated with less improvement after 6 months of lithium- or quetiapine-based treatment.

AB - Objective: Examine the effects of obesity and metabolic syndrome on outcome in bipolar disorder. Method: The Comparative Effectiveness of a Second Generation Antipsychotic Mood Stabilizer and a Classic Mood Stabilizer for Bipolar Disorder (Bipolar CHOICE) study randomized 482 participants with bipolar disorder in a 6-month trial comparing lithium- and quetiapine-based treatment. Baseline variables were compared between groups with and without obesity, with and without abdominal obesity, and with and without metabolic syndrome respectively. The effects of baseline obesity, abdominal obesity, and metabolic syndrome on outcomes were examined using mixed effects linear regression models. Results: At baseline, 44.4% of participants had obesity, 48.0% had abdominal obesity, and 27.3% had metabolic syndrome; neither obesity, nor abdominal obesity, nor metabolic syndrome were associated with increased global severity, mood symptoms, or suicidality, or with poorer functioning or life satisfaction. Treatment groups did not differ on prevalence of obesity, abdominal obesity, or metabolic syndrome. By contrast, among the entire cohort, obesity was associated with less global improvement and less improvement in total mood and depressive symptoms, suicidality, functioning, and life satisfaction after 6 months of treatment. Abdominal obesity was associated with similar findings. Metabolic syndrome had no effect on outcome. Conclusion: Obesity and abdominal obesity, but not metabolic syndrome, were associated with less improvement after 6 months of lithium- or quetiapine-based treatment.

KW - Bipolar disorder

KW - Metabolic syndrome

KW - Obesity

KW - Outcome

UR - http://www.scopus.com/inward/record.url?scp=84953836575&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84953836575&partnerID=8YFLogxK

U2 - 10.1111/acps.12460

DO - 10.1111/acps.12460

M3 - Article

VL - 133

SP - 144

EP - 153

JO - Acta Psychiatrica Scandinavica

JF - Acta Psychiatrica Scandinavica

SN - 0001-690X

IS - 2

ER -